US Antimony (UAMY) Stock Skyrockets on $245M Defense Deal – Is It Too Good to Be True?

🚀 UAMY Stock Explodes on Montana Mining Breakthrough – What Investors Need to Know

  • Ticker: NYSE American (UAMY). Closed Nov 1 at $8.07 [1]; 52-week high $19.71 (Oct 14, 2025) [2]. Market cap ≈$1.12B [3].
  • Premarket Nov 3: ~$8.03 (flat) expected [4]. Volatility high – last session saw ~13M shares traded [5] (far above normal).
  • Antimony Focus: U.S. Antimony is North America’s only fully integrated antimony producer outside China [6]. Antimony is a critical mineral (used in flame retardants and munitions), and prices recently hit record highs (~$51,500/ton) on global demand [7] [8].
  • Recent Developments: On Oct 30, US Antimony announced a “game changer” restart of its Stibnite Hill, MT mine after 40 years. The company shipped 250+ tons of ore on day one and raised FY2026 revenue guidance by $25M to $125M [9] [10]. The CEO said mining in-house ore yields ~3× the profit margins [11].
  • Defense Contract: In Sept 2025 the company won a $245M sole-source Pentagon contract to supply antimony, assuring multi-year demand [12]. This underpins USAC’s growth plans.
  • Financial Results: Q2 2025 revenue soared +160% YoY to $17.53M, gross profit +183% (to $5.21M), with net income $728K (vs. –$120K LY) [13]. Antimony sales alone jumped 203% to $15.56M [14]. Management reaffirmed FY2025 revenue guidance of $40–50M (fuelled by higher antimony prices).
  • Capital Raise: In Oct 2025 the company raised $25M via a direct stock offering (no discount) [15] – part of ~$69M raised YTD [16]. Proceeds fund inventory build-up (for the Pentagon contract), mine expansion (Alaska, Montana), and smelter capacity in Mexico.
  • Operations Update: USAC is expanding its Thompson Falls, MT smelter (new furnaces due Jan 2026 [17]), retrofitting 4 furnaces (complete) [18], and acquiring land in Montana/Alaska [19] [20]. It also completed a $5M tungsten mine acquisition in Canada [21].
  • Industry Peers: U.S. Antimony owns 2 of only 3 antimony smelters in the Western Hemisphere [22]. Its ASX-listed peer Larvotto Resources (Australian antimony developer) recently rejected USAC’s A$723M takeover bid (deeming it undervalued) [23]. In the broader rare-earth/minerals sector, stocks like USA Rare Earth (USAR) have more than tripled YTD on U.S. govt support [24]; MP Materials (MP) saw the U.S. defense build new magnet capacity (15% DOD stake) [25]. (UAMY is often cited in the same “critical minerals” stock themes [26].)
  • Analyst & Insider: William Blair initiated UAMY as “Outperform” on Oct 20 [27]. (Consensus 1-year price targets were ~$8.58–$10.24 previously [28], though that’s now below current price.) Notably, CEO Gary Evans bought 100,000 shares (~$613K) in Oct, showing insider confidence [29]. The stock’s put/call ratio (~0.62) also suggests bullish sentiment.
  • Technical Outlook: UAMY is trading well below mid-October highs, and many indicators are oversold. One technical model flags RSI(~24) as deeply oversold [30]. That same model (stockinvest.us) even projects a possible ~98% rally in 3 months (to ~$16–38) [31], though this is highly aggressive. For Nov 3, it estimates a fair open near $8.03 (virtually unchanged) and an intra-day range ~$7.24–$8.90 [32] [33]. Key support is around $7.30–$7.55 [34]; resistance near $8.40–$9.50 (next MA levels) [35].

Montana’s Stibnite Hill – site of US Antimony’s recent mining “game changer.” CEO Gary Evans says self-mined ore triples profit margins [36], enabling a $25M guidance boost [37].

In-Depth Analysis

Montana Mining Breakthrough & Larvotto Update

This week’s biggest catalyst was the restart of the Stibnite Hill mine. US Antimony reported that after federal approval it began a “cut and cover” operation, hauling ore quickly to its flotation mill [38]. The company called it a “game changer” — Chairman/CEO Gary Evans noted margins on self-mined ore would be roughly three times higher than buying externally [39]. Reflecting this, USAC raised FY2026 revenue guidance from $100M to $125M [40]. Mining.com’s report noted the stock rallied ~10% premarket on this news [41].
Notably, USAC also disclosed it will not pursue acquisition talks with Larvotto after Larvotto’s board rejected USAC’s ~A$723M bid [42]. USAC still holds ~10% of Larvotto’s stock [43]. (Larvotto itself said USAC’s implied offer had fallen to A$1.11/share vs an initial A$1.40 due to UAMY’s slide [44].) With Larvotto off the table, USAC can focus on organic growth while keeping a strategic stake in the Australian antimony asset.

Operations & Financials

US Antimony is accelerating expansion. In April 2025 it contracted WSP USA to expand its Thompson Falls smelter [45]; four upgraded furnaces are now online [46], and two more furnaces are expected by Jan 2026 to double metal output [47]. The company has also been quietly acquiring antimony claims in Alaska and Montana (Jan 2025) and entered an option to control more Alaska antimony claims [48] [49]. It even picked up a $5M tungsten mine in Canada to hedge against processing bottlenecks [50].

On the numbers side, USAC’s first-half 2025 results were stellar. Q1 revenue jumped 128% YoY to $7.0M [51]. In Q2, antimony drove an even bigger surge: revenue was $17.53M (+160%), gross profit $5.21M (+183%), and net income $0.728M (vs –$0.12M prior year) [52]. Notably, antimony product sales reached $15.56M (+203%) in Q2 [53]. Higher antimony prices and tighter supply (China cuts exports) powered these gains. The company now holds record inventory (~201 tons of antimony, ~$10.4M) to feed its smelters and the Pentagon contract [54].

To fund growth, USAC has raised equity aggressively. In 2025 it raised a total ~$69M (three tranches) from institutional investors [55]. The latest was a $25M direct offering in early Oct at above-market prices [56]. CEO Evans noted these financings were done “with minimal or no discounts” [57], bringing stronger shareholders on board. Proceeds are earmarked for antimony inventory, mineral leases (Alaska/Montana), expanding the Mexican smelter (Madero), and acquisitions.

Stock Price & Trading Snapshot

After a wild ride in October, UAMY is trading off its highs. As of the last U.S. close (Nov 1), UAMY was $8.07 [58], about 60% below its Oct 14 peak ($19.71 [59]). Trading volume has been heavy — roughly 13 million shares changed hands on Friday [60] (far above its ~2–3M pre-surge norm). The stock is currently down ~3% on the week. Analysts note the forward P/E (TTM) is very high (~154× as of Oct 31 [61]), reflecting low current profits and high growth expectations.

Investors will watch Monday’s premarket action closely. One technical model (stockinvest.us) forecasts an open around $8.03 [62] and a wide intraday range $7.24–$8.90 [63] (±22%). Key support is around $7.30–$7.55 and resistance near $8.40–$9.50 (10-day/50-day moving averages) [64] [65]. Many indicators are stretched: the stock is deeply oversold on RSI (≈24) [66], and short interest has climbed (ambiguous). In the short term, any positive volume or contract news could spark a bounce.

Expert Commentary & Sector Peers

Market commentators are taking notice. Mining.com and Investing.com both covered the Montana mine restart, quoting Evans’s comments on the new margins and guidance boost [67] [68]. A Reuters note (Sept 23) had already highlighted the Pentagon contract’s importance [69]. On Wall Street, William Blair recently initiated UAMY at “Outperform” [70]. (Note: earlier price targets ~$9–$10 implied downside from then-$11 prices [71], but those are now outdated.) Hedge funds and institutions have been accumulating; e.g. several filings show Vanguard, BlackRock, Geode, Citadel and others adding millions of shares recently. Insider buying by the CEO (100k shares in Oct) [72] and a sub-1 put/call ratio signal bullish conviction.

Comparatively, UAMY’s story sits within a broader U.S. critical-minerals boom. USA Rare Earth (USAR), a Texas rare-earth miner, just jumped 18% after saying it’s “in close communication” with the White House, and has tripled in 2025 on optimism about federal support [73]. MP Materials (MP), a U.S. rare-earth company, secured a 15% Dept. of Defense stake in its $1.2B magnet production deal [74]. Even cobalt and lithium miners (e.g. Lithium Americas) have seen government backing. UAMY’s antimony is similarly critical for defense (used in primers, armor, etc.), so it’s often mentioned by strategists as a beneficiary of “reshoring” policies [75] [76].

On the Australian side, Larvotto Resources is the only other pure-play antimony stock in USAC’s orbit. Larvotto’s recent +9.7% jump [77] came solely from rejecting UAMY’s bid. The fate of Larvotto’s Stibnite (Idaho) project may still be relevant, but for now UAMY shifts focus to its own Montana and Alaska assets.

Outlook & Forecast

In the very near term, UAMY’s stock will hinge on trading sentiment: is the Montana breakthrough “baked in,” or will buyers return to these oversold levels? The premarket forecast (~$8.0) suggests the market is treading cautiously [78]. If the stock holds above ~$7.50 support, a technical rebound is plausible. Over the next few weeks, additional catalysts could include drill or production updates from Stibnite Hill, progress on the smelter buildout, or any defense stockpile news.

Fundamentally, US Antimony has rarely looked stronger: it boasts secured demand (DoD contract), rising commodity prices, and multiple growth projects. Even after the recent pullback, one quantitative model (admittedly optimistic) predicts a 90% chance UAMY could double in 3 months to ~$16–38 [79]. More moderately, Wall Street’s own surveys (4 analysts) pointed to price targets in the low-$10’s (implying some upside from today’s ~$8, but not a tripling). Given the volatility, many investors may take a step back: as stockinvest.us warns, “No buy recommendation” (the model has a sell rating) in the near term [80]. Ultimately, UAMY looks set for strong growth, but it may need to digest recent gains and overcome technical resistance before the next leg up.

Sources: Company press releases [81] [82]; Mining.com and Investing.com news [83] [84]; Reuters [85] [86] [87]; Stock analysis and filings [88] [89] [90]; industry reports [91] [92], etc.

US Antimony Corp starts mining

References

1. www.reuters.com, 2. www.reuters.com, 3. www.reuters.com, 4. stockinvest.us, 5. stockinvest.us, 6. www.nasdaq.com, 7. investingnews.com, 8. investingnews.com, 9. www.investing.com, 10. www.mining.com, 11. www.investing.com, 12. www.reuters.com, 13. www.stocktitan.net, 14. www.stocktitan.net, 15. www.nasdaq.com, 16. www.nasdaq.com, 17. www.mining.com, 18. www.stocktitan.net, 19. www.usantimony.com, 20. www.nasdaq.com, 21. www.stocktitan.net, 22. www.investing.com, 23. www.investing.com, 24. www.tikr.com, 25. www.tikr.com, 26. investingnews.com, 27. www.quiverquant.com, 28. www.nasdaq.com, 29. www.quiverquant.com, 30. stockinvest.us, 31. stockinvest.us, 32. stockinvest.us, 33. stockinvest.us, 34. stockinvest.us, 35. stockinvest.us, 36. www.investing.com, 37. www.investing.com, 38. www.investing.com, 39. www.investing.com, 40. www.mining.com, 41. www.investing.com, 42. www.mining.com, 43. www.mining.com, 44. www.investing.com, 45. www.usantimony.com, 46. www.stocktitan.net, 47. www.mining.com, 48. www.usantimony.com, 49. www.nasdaq.com, 50. www.stocktitan.net, 51. www.usantimony.com, 52. www.stocktitan.net, 53. www.stocktitan.net, 54. www.stocktitan.net, 55. www.nasdaq.com, 56. www.nasdaq.com, 57. www.nasdaq.com, 58. www.reuters.com, 59. www.reuters.com, 60. stockinvest.us, 61. www.reuters.com, 62. stockinvest.us, 63. stockinvest.us, 64. stockinvest.us, 65. stockinvest.us, 66. stockinvest.us, 67. www.investing.com, 68. www.mining.com, 69. www.reuters.com, 70. www.quiverquant.com, 71. www.nasdaq.com, 72. www.quiverquant.com, 73. www.tikr.com, 74. www.tikr.com, 75. www.investing.com, 76. investingnews.com, 77. www.investing.com, 78. stockinvest.us, 79. stockinvest.us, 80. stockinvest.us, 81. www.nasdaq.com, 82. www.nasdaq.com, 83. www.mining.com, 84. www.investing.com, 85. www.reuters.com, 86. www.investing.com, 87. www.reuters.com, 88. www.stocktitan.net, 89. www.quiverquant.com, 90. stockinvest.us, 91. www.tikr.com, 92. investingnews.com

Stock Market Today

  • ANI Pharmaceuticals (ANIP) Valuation: Fair Value of $105 After 2024 Rally
    November 3, 2025, 12:56 AM EST. ANI Pharmaceuticals (ANIP) has rallied in 2024, delivering a 63.4% year-to-date gain and a 55.7% trailing twelve-month return, signaling momentum for long-term holders. The bull case centers on a $105 fair value-about 13-14% above the last close-which suggests the stock could still be undervalued. Growth drivers include continued expansion in the Rare Disease portfolio, increased sales force, and new product launches boosting margins and EBITDA. However, ongoing competition in generics and tighter payer controls on ACTH pricing could cap upside. If investors want more, the piece promises deeper analysis and potential risks. The article frames a narrative where profits and an aggressive expansion strategy could justify the depicted valuation, while noting uncertainties that could temper gains.
  • WSFS Financial Valuation Revisited After Recent Share Dip
    November 3, 2025, 12:00 AM EST. WSFS Financial (WSFS) shares dipped ~2% over the past week as investors weigh macro conditions and regional bank sentiment. Year-to-date momentum remains modest, with a solid 6.2% total shareholder return over the past year. The stock trades about 21% below analyst targets, yet a popular narrative pegs the fair value at $64.50, suggesting the stock is undervalued. Key drivers cited include population growth, rising deposits in suburban and mid-Atlantic markets, and stronger mortgage origination, hinting at continued revenue and deposit growth. Risks include integration challenges from acquisitions or a regional downturn that could curb growth and alter valuation. Overall, the question is whether the market has already priced future expansion, and investors may want to examine the broader narrative behind the upside.
Adobe’s AI Foundry Unveiled: Custom Brand AI Models and What Investors Are Saying
Previous Story

Premarket: Adobe (ADBE) Stock Slumps on AI Concerns — Monday Outlook & Key Catalysts

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside
Next Story

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Go toTop